FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1973245611> ?p ?o ?g. }

• W1973245611 endingPage "25" @default.
• W1973245611 startingPage "22" @default.
• W1973245611 abstract "In this randomized double‐blind trial, two new antifungal compounds were compared in patients with interdigital or more extensive forms of tinea pedis. Two weeks of oral treatment with either terbinafine, an allylamine and new chemical entity, 250 mg daily, or itraconazole 100 mg daily, was given to 366 patients (184 terbinafine, 182 itraconazole). Of 13 patients who did not return after the first visit, 11 were lost to follow‐up (five on terbinafine, six on itraconazole) and two reported adverse events. Another nine patients (three on terbinafine and six on itraconazole) were excluded because it was uncertain to which group they were randomized. A central laboratory performed both the mycology and safety tests. In 355 patients who received the study medications and were available for analysis of side‐effects, 18 out of 179 (10·0%) in the terbinafine group and 10 out of 176 (5·7%) in the itraconazole group reported adverse events. No new clinically significant laboratory abnormalities were seen after treatment. At week 8 the efficacy analysis in 117 patients with mycologically confirmed dermatophyte infections (51 on terbinafine, 66 on itraconazole) showed that clinical symptoms were absent or minimal in 94·1% of the terbinafine and 72·7% of the itraconazole group (P=0·0095); mycology was negative in 86·3% of the terbinafine and 54·5% of the itraconazole group (P=0·0002). With terbinafine, negative mycology at week 8 was 81.3% in the interdigital and 88·6% in the more extensive forms of tinea pedis; with itraconazole mycology was negative in 65·0% and 50·0% of patients, respectively. This study demonstrates that the primary fungicidal action of terbinafine, i.e. its ability to kill fungi at minimal inhibitory concentrations, is of substantial clinical and economic benefit to patients with tinea pedis. After a 2‐week oral treatment period of any form of tinea pedis, terbinafine produced significantly higher mycological cure rates and significantly better clinical improvement than itraconazole." @default.
• W1973245611 created "2016-06-24" @default.
• W1973245611 creator A5006211659 @default.
• W1973245611 creator A5041590207 @default.
• W1973245611 creator A5045095264 @default.
• W1973245611 creator A5061037089 @default.
• W1973245611 date "1994-04-01" @default.
• W1973245611 modified "2023-10-15" @default.
• W1973245611 title "Two-week oral treatment of tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): a double-blind, multicentre study" @default.
• W1973245611 cites W2107030537 @default.
• W1973245611 cites W2123162635 @default.
• W1973245611 doi "https://doi.org/10.1111/j.1365-2133.1994.tb06089.x" @default.
• W1973245611 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8186137" @default.
• W1973245611 hasPublicationYear "1994" @default.
• W1973245611 type Work @default.
• W1973245611 sameAs 1973245611 @default.
• W1973245611 citedByCount "48" @default.
• W1973245611 countsByYear W19732456112012 @default.
• W1973245611 countsByYear W19732456112013 @default.
• W1973245611 countsByYear W19732456112015 @default.
• W1973245611 countsByYear W19732456112018 @default.
• W1973245611 countsByYear W19732456112019 @default.
• W1973245611 countsByYear W19732456112020 @default.
• W1973245611 countsByYear W19732456112022 @default.
• W1973245611 countsByYear W19732456112023 @default.
• W1973245611 crossrefType "journal-article" @default.
• W1973245611 hasAuthorship W1973245611A5006211659 @default.
• W1973245611 hasAuthorship W1973245611A5041590207 @default.
• W1973245611 hasAuthorship W1973245611A5045095264 @default.
• W1973245611 hasAuthorship W1973245611A5061037089 @default.
• W1973245611 hasConcept C126322002 @default.
• W1973245611 hasConcept C16005928 @default.
• W1973245611 hasConcept C197934379 @default.
• W1973245611 hasConcept C2777071850 @default.
• W1973245611 hasConcept C2777220567 @default.
• W1973245611 hasConcept C2778236110 @default.
• W1973245611 hasConcept C2779548794 @default.
• W1973245611 hasConcept C71924100 @default.
• W1973245611 hasConceptScore W1973245611C126322002 @default.
• W1973245611 hasConceptScore W1973245611C16005928 @default.
• W1973245611 hasConceptScore W1973245611C197934379 @default.
• W1973245611 hasConceptScore W1973245611C2777071850 @default.
• W1973245611 hasConceptScore W1973245611C2777220567 @default.
• W1973245611 hasConceptScore W1973245611C2778236110 @default.
• W1973245611 hasConceptScore W1973245611C2779548794 @default.
• W1973245611 hasConceptScore W1973245611C71924100 @default.
• W1973245611 hasIssue "s43" @default.
• W1973245611 hasLocation W19732456111 @default.
• W1973245611 hasLocation W19732456112 @default.
• W1973245611 hasOpenAccess W1973245611 @default.
• W1973245611 hasPrimaryLocation W19732456111 @default.
• W1973245611 hasRelatedWork W1968026013 @default.
• W1973245611 hasRelatedWork W1973245611 @default.
• W1973245611 hasRelatedWork W1996950720 @default.
• W1973245611 hasRelatedWork W2029928367 @default.
• W1973245611 hasRelatedWork W2036214634 @default.
• W1973245611 hasRelatedWork W2064532674 @default.
• W1973245611 hasRelatedWork W2147481118 @default.
• W1973245611 hasRelatedWork W2463449047 @default.
• W1973245611 hasRelatedWork W4229676201 @default.
• W1973245611 hasRelatedWork W4244144176 @default.
• W1973245611 hasVolume "130" @default.
• W1973245611 isParatext "false" @default.
• W1973245611 isRetracted "false" @default.
• W1973245611 magId "1973245611" @default.
• W1973245611 workType "article" @default.